Understand the source comparison
Best Peptides for Women 45-55 Perimenopause: Protocol Comparison
CJC-1295/Ipamorelin Stimulates pulsatile GH secretion; improves lipolysis and lean mass retention 200–300mcg each, 3–5×/week subcutaneous Body composition changes visible at 8–12 weeks; metabolic markers improve at 4–6 weeks Moderate. Multiple observational st
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- CJC-1295/Ipamorelin
- Stimulates pulsatile GH secretion; improves lipolysis and lean mass retention
- 200–300mcg each, 3–5×/week subcutaneous
- Body composition changes visible at 8–12 weeks; metabolic markers improve at 4–6 weeks
- Moderate. Multiple observational studies, limited RCTs in perimenopausal populations
- Best for women prioritizing lean mass preservation and metabolic rate. Requires consistent administration
- Tirzepatide (GLP-1/GIP agonist)
- Restores insulin sensitivity; reduces visceral fat; suppresses appetite via incretin signaling
- 2.5–15mg weekly subcutaneous, titrated over 20 weeks
- Appetite suppression within 1 week; meaningful weight loss (5%+) at 8–12 weeks
- Strong. Phase III RCTs (SURMOUNT) with robust endpoints
- Most effective single intervention for insulin resistance and visceral fat. GI side effects require titration
- MOTS-c (mitochondrial peptide)
- Enhances mitochondrial biogenesis; restores metabolic flexibility and glucose uptake
- 5–15mg 2–3×/week subcutaneous
- Energy and exercise tolerance improve at 2–4 weeks; metabolic markers at 6–8 weeks
- Emerging. Preclinical and early clinical data; Phase II trials ongoing
- Addresses energy and metabolic flexibility specifically. Pairs well with GLP-1 agonists
- Semax (nootropic)
- Increases BDNF; enhances synaptic plasticity and cognitive resilience
- 300–600mcg intranasal, 1–2×/day
- Cognitive clarity improves within 3–7 days; sustained effects require daily use
- Moderate. Primarily Eastern European clinical data; limited Western RCTs
- Best for cognitive fog and focus issues. Effects are acute and dose-dependent
- BPC-157 (tissue repair peptide)
- Promotes angiogenesis; accelerates soft tissue and joint healing
- 250–500mcg daily subcutaneous or oral
- Tissue healing visible at 2–4 weeks for acute injuries; chronic issues require 6–8 weeks
- Weak. Animal models strong, human RCT data limited
- Useful for joint pain or injury recovery common in this age group. Not a metabolic or hormonal intervention